With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...
Pharmaceutical Technology on MSN
China’s NMPA approves Sanofi’s rare haematologic disease treatments
China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...
China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...
Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...
Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) ...
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...
A forward-looking analysis of how nonfactor therapies are transforming patient quality of life, clinician-patient collaboration, and the broader healthcare ecosystem for hemophilia management. The MHE ...
Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...
Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the International ...
ATLAS trial investigator Guy Young, MD, Children's Hospital Los Angeles and University of Southern California Keck School of Medicine, highlights the current treatment options for patients with ...
Dose and frequency should be adjusted based on antithrombin activity, using the Innovance Antithrombin companion diagnostic test. The Food and Drug Administration (FDA) has approved Qfitlia (fitusiran ...
Sanofi and Alnylam’s fitusiran (Qfitlia) has secured FDA approval for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and paediatric patients 12 years of age and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback